MAFSofosbuvir & Velpatasvir Tablet, Sofosbuvir 400 mg + Velpatasvir 100 mg
Treatment of chronic hepatitis C infection (all genotypes) in treatment-naïve, or pegylated interferon plus ribavirin (PR)-experienced or NS3/4A protease inhibitor (boceprevir, simeprevir, telaprevir)-experienced adults.
Sofosbuvir/velpatasvir should be used in line with the recommended treatment regimen and duration:
• 12 weeks’ treatment of sofosbuvir/velpatasvir for patients with hepatitis C virus (all genotypes) without cirrhosis or with compensated cirrhosis (Child-Pugh A). For patients with genotype 3, the addition of ribavirin may be considered in patients who are treatment-experienced or have compensated cirrhosis (Child-Pugh A).
• 12 weeks’ treatment of sofosbuvir/velpatasvir in combination with ribavirin for patients with hepatitis C virus (all genotypes) with decompensated cirrhosis (Child-Pugh B or C).
Sofosbuvir/velpatasvir should be prescribed by a specialist physician (gastroenterologist, hepatologist, or infectious disease specialist) with experience in treating hepatitis C.